Quarterly Result30 Jul 2026, 03:56 pm
Mankind Pharma Q1FY27 Revenue Up 12.9% to ₹4,031 Cr
AI Summary
Mankind Pharma announced its financial results for the first quarter ended June 30, 2026, reporting a robust 12.9% year-on-year revenue growth to ₹4,031 Crore. EBITDA saw a significant increase of 24.7% to ₹1,060 Crore, with EBITDA margins improving by 250 basis points to 26.3%. Profit After Tax (PAT) grew by 29.1% to ₹574 Crore, and PAT margin expanded by 170 basis points to 14.2%. The company's domestic business, excluding Consumer Healthcare, grew by 11.0%, driven by strong performance in chronic therapies and specialty segments. The international business also showed strong momentum, with revenue up 29.0%. Diluted EPS increased by 29.6% to ₹13.7.
Key Highlights
- Revenue grew 12.9% YoY to ₹4,031 Cr.
- EBITDA increased 24.7% YoY to ₹1,060 Cr, with margins at 26.3%.
- PAT grew 29.1% YoY to ₹574 Cr, with margins at 14.2%.
- Domestic business (ex-CH) grew 11.0% YoY.
- International business revenue surged 29.0% YoY.
Price Impact
More from MANKIND